Precision

SkinPen® Precision Wins Prestigious Aesthetics Awards 2024 for "Best Energy Device of the Year"

Retrieved on: 
Thursday, March 21, 2024
Health, Patient, Ageing, Medical device, Dyschromia, Patient satisfaction, Safety, Precision, FDA, Neck

This prestigious award recognizes the remarkable impact SkinPen Precision has had in advancing healthcare through cutting-edge technology and superior patient outcomes.

Key Points: 
  • This prestigious award recognizes the remarkable impact SkinPen Precision has had in advancing healthcare through cutting-edge technology and superior patient outcomes.
  • The Aesthetics Awards are the most prestigious and longest-standing awards ceremony in the UK medical aesthetics specialty.
  • Backed by over 90 clinical studies and extensive clinical data, SkinPen Precision is a game-changer in the aesthetics' landscape.
  • CE Mark – Medical Device Class IIa:
    Medical Purpose: SkinPen Precision Microneedling System is a medical device intended to treat facial acne scars in adults aged 22 years or older.

Norfolk Southern appoints industry veteran John Orr as chief operating officer

Retrieved on: 
Wednesday, March 20, 2024
Growth, CPKC, Precision, Harvard Business School, History, Acquisition, Advanced Management Program, Transport, University, NS, Meridian Speedway, Safety, University of Waterloo, KCS, Shaw, National Railway, NSC, Engineering, Management

ATLANTA, March 20, 2024 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) announced Wednesday the appointment of John Orr as executive vice president and chief operating officer, effective immediately. Throughout his four-decade career, Orr has earned a reputation as a proven leader in applying scheduled railroading principles to drive sustainable long-term value creation. He spearheaded the turnaround of Canadian Pacific Kansas City's (CPKC) Mexico operations by successfully implementing a high-efficiency operating model, shaped and guided the execution of Kansas City Southern's (KCS) service-focused scheduled railroading initiatives, and drove significant improvements in Canadian National Railway's (CN) safety and operational performance.

Key Points: 
  • ATLANTA, March 20, 2024 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) announced Wednesday the appointment of John Orr as executive vice president and chief operating officer, effective immediately.
  • He will report directly to Norfolk Southern president and chief executive officer Alan H. Shaw.
  • In connection with Orr's appointment, current chief operating officer Paul Duncan departed the company to pursue other opportunities.
  • Alan Shaw, Norfolk Southern president and chief executive officer, said, "John is a deeply respected and accomplished leader, and is the right chief operating officer to ensure execution of our strategy of balancing safe service, productivity, and growth.

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
CD20, Conference call, European Commission, Patent, CD19, Precision, Precision BioSciences, Conference, Multiple sclerosis, Consultant, Therapy, Patient, Autoimmunity, Clinical trial, Finance, RMS, Prescription, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “2023 was an exciting year of execution for TG, which we believe has set the stage for a successful 2024. The BRIUMVI launch exceeded our expectations, and we ended the year with approximately $89 million in U.S. net revenue and provided a BRIUMVI U.S. net revenue target of $220 - $260 million for 2024. Further executing on our corporate objectives in 2023, we presented the first data from our ENHANCE Phase 3 b trial evaluating patients who switch from prior CD20 therapy to BRIUMVI, and recently broadened our BRIUMVI clinical efforts to include subcutaneous development and potential expansion beyond MS. We look forward to sharing additional developments from these efforts throughout the year, as well as advancing our recent pipeline addition, azer-cel, an allogeneic CAR T into clinical development in autoimmune disease.” Mr. Weiss continued, “We were also pleased to see our ex-US partner, Neuraxpharm, commence the launch of BRIUMVI in Europe this week. As the year progresses, we look forward to providing continued updates on our launch of BRIUMVI in the U.S. and sharing data updates throughout the year at major medical meetings.”

Key Points: 
  • Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively
    Conference call to be held today, February 28, 2024, at 8:30 AM ET
    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $217.5 million as of December 31, 2023.
  • The Company will host a conference call today, February 28, 2024, at 8:30 AM ET, to discuss the Company’s financial results from the fourth quarter and full year ended December 31, 2023.
  • To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics.

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Retrieved on: 
Wednesday, March 6, 2024
Other Health, Research, General Health, Pharmaceutical, Technology, Genetics, Clinical Trials, Science, Nanotechnology, Biotechnology, Other Science, Health, Liver, Nerve, Metabolic disorder, Precision BioSciences, Gene editing, Ammonia, Coma, TGA, Ornithine transcarbamylase deficiency, Blood, OTC, Precision, Risk, Health care, Death, Patient, MHRA, Disease, IND, CTA

Medicines & Healthcare products Regulatory Agency (MHRA) for the company’s Clinical Trial Authorization (CTA) application to expand the Phase 1/2 OTC-HOPE study evaluating ECUR-506 into the U.K.

Key Points: 
  • Medicines & Healthcare products Regulatory Agency (MHRA) for the company’s Clinical Trial Authorization (CTA) application to expand the Phase 1/2 OTC-HOPE study evaluating ECUR-506 into the U.K.
  • The OTC-HOPE study is investigating ECUR-506, incorporating an ARCUS nuclease, for the treatment of Ornithine Transcarbamylase (OTC) deficiency in infants.
  • In 2021, Precision licensed to iECURE an ARCUS nuclease that inserts a functional copy of the OTC gene for treatment of OTC deficiency.
  • “Congratulations to iECURE for bringing the first gene editing approach into clinical investigation for patients with OTC deficiency.

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Retrieved on: 
Friday, March 1, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Janus, Attention, Prospectus, Precision BioSciences, Gene editing, Telephone, Floor, Sale, Precision, Madison Avenue, Guggenheim Partners, Security (finance)

The warrants have an exercise price of $20.00 per share and are exercisable immediately and will expire five years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $20.00 per share and are exercisable immediately and will expire five years following the date of issuance.
  • The financing consisted of participation from leading life sciences investors, including Perceptive Advisors, Janus Henderson Investors, Aquilo Capital Management, LLC and LYFE Capital.
  • In addition, Precision BioSciences has granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of its common stock and/or warrants to purchase up to 375,000 shares of common stock, at the combined public offering price and less underwriting discounts and commissions.
  • All shares of common stock and accompanying warrants to be sold in the offering will be sold by Precision.

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

Retrieved on: 
Thursday, February 29, 2024
Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, General Health, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Attention, Prospectus, Gene editing, Telephone, Floor, Sale, Precision, Precision BioSciences, Madison Avenue, Guggenheim Partners, Security (finance)

Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced the commencement of a proposed underwritten public offering of its common stock and accompanying warrants to purchase shares of common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced the commencement of a proposed underwritten public offering of its common stock and accompanying warrants to purchase shares of common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers.
  • All shares of common stock, pre-funded warrants and accompanying warrants to be sold in the proposed offering will be sold by Precision.
  • The pre-funded warrants will be issued to certain purchasers who have elected to purchase them in lieu of shares of common stock in this offering.
  • Precision also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock and warrants to purchase shares of common stock (including shares underlying the pre-funded warrants) to be offered at the public offering price, less the underwriting discount.

Boulevard Education Manager Jozlyn Miller Named Mainstage Presenter at the Data-Driven Salon Summit 2024

Retrieved on: 
Wednesday, February 28, 2024
Technology, Cosmetics, Alternative Medicine, Retail, Health, Other Health, Vitamins, Supplements, Luxury, Mental Health, Software, General Health, Fitness & Nutrition, Data Management, Fashion, Well, Erigeron, Melksham, Platinum, Growth, Day, Precision, Data, Communication, Knowledge, Miller, Beauty, Beauty salon

Boulevard ( www.joinblvd.com ), provider of the client experience platform purpose-built for appointment-based, self-care businesses, today announced that Jozlyn Miller, the company’s senior education manager, has been named a mainstage presenter at the Data-Driven Salon Summit 2024 .

Key Points: 
  • Boulevard ( www.joinblvd.com ), provider of the client experience platform purpose-built for appointment-based, self-care businesses, today announced that Jozlyn Miller, the company’s senior education manager, has been named a mainstage presenter at the Data-Driven Salon Summit 2024 .
  • “Education is essential to the continued growth and success of the salon industry, and there’s no better educational experience out there right now than the Data-Driven Salon Summit.
  • Produced by SALON TODAY, the 2024 summit will specifically focus on key power metrics including average ticket, productivity, client retention , client count, and percentage of service guests purchasing retail.
  • “We are excited to welcome Jozlyn back to the Data-Driven stage for another engaging presentation,” says Stacey Soble, director of brand content strategy for SALON TODAY.

AGCO’s Fendt®, Massey Ferguson®, Precision Planting® & GSI® Offer Expansive, Farmer-Focused Exhibit at 2024 Commodity Classic

Retrieved on: 
Wednesday, February 21, 2024
Technology, Manufacturing, Agritech, Agriculture, Natural Resources, Machinery, Momentum, Soil, Fendt, IDEAL, Farmer, Grain, Symphony, GSI, Gleaner, Precision, Sprayer, Series, Rollo Davidson Prize, 8S, Vario, AGCO, Feed, Radicle, Film industry

Fendt produces some of agriculture’s most innovative solutions, and its booth at Commodity Classic will be teeming with AE50 award winners.

Key Points: 
  • Fendt produces some of agriculture’s most innovative solutions, and its booth at Commodity Classic will be teeming with AE50 award winners.
  • Rounding out Fendt’s exhibit will be its Mobile Experience Center, which provides hands-on simulator experiences of the brand’s machines.
  • Massey Ferguson’s exhibit will also include its VE Series Planter , which leverages Precision Planting® technology to maximize farmers’ return on investment, save time and increase yields.
  • Precision Planting’s display at Commodity Classic will showcase solutions from every season of the crop cycle.

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Retrieved on: 
Tuesday, February 20, 2024
Research, Pharmaceutical, Technology, Genetics, Fitness & Nutrition, Clinical Trials, Science, Nanotechnology, Biotechnology, Stem Cells, Other Science, Health, Therapy, TRAC, Patent, Reindeer, CRISPR, Gene editing, Precision, Precision BioSciences

This approach is proprietary to Precision and results in T cells suitable for allogeneic use.

Key Points: 
  • This approach is proprietary to Precision and results in T cells suitable for allogeneic use.
  • Under the terms of the agreement, Precision will receive an upfront payment and, upon commercialization by Caribou, royalties on net sales of licensed products.
  • In addition, for each occurrence of certain strategic transactions involving Caribou, Precision is eligible to receive a specific tiered milestone payment.
  • This patent family is potentially also available for non-exclusive license to other high-quality partners in the cell therapy space.

EudraVigilance - EVWEB user manual

Retrieved on: 
Sunday, March 10, 2024
International Organization (journal), Level 2, Automation, Chapter Two, ACK, ISO, Classification, SSL, Sender, Clinical trial, Radio, Immediate, European, CAPS, European Medicines Agency, Report, MDN, ICH, Medicine, HTML, Internet, Medical dictionary, NCA, Originality, HTTPS, SHTTP, European Economic Area, Headquarters, NASK, Three-body problem, Privacy, Match, Database, Data entry, European Economic Community, MSSO, Module, ZIP, Acknowledgment, Acronym, Environment, Message, MLM, Access, Conference, Pharmacovigilance, XML, EMA, Gateway, Chapter One, MedDRA, Active ingredient, Communication, Validation, Public, Data analysis, Precision, RTF, Navigation, Salt, Security, Chapter Five, Contextual, International organization, Convention, SME, URL, Chapter Four, ID, MAH, Rich Text Format, Microsoft Edge, EudraVigilance, Name, MSK, UNK, Risk, Create, Tree view, ICSR, Chapter Three, Web browser, Commercial, R2, Socs, TAB, Literature, Courier, CIOMS, EV, Built-in self-test, Documentation, Coreidae, Council, S-HTTP, File Explorer, UI, Import, Calendar, WEB, Reproduction, Jousting, PDF, Economic union, Mobile phone
Key Points: